Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Name: Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
Published: 2023
License: Public Domain

Catalysis SL · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

immunomodulation

papilloma viral infection, cin1, lsil, low grade squamous intraepithelial lesion, glycyrrhizinic acid, lsil/cin1, cervical adenocarcinoma, immunomodulation, interventional, phase4

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Related documents